Nonacog Beta Pegol
From PeptidePlaza, the free peptide reference · Entry #1203 · Recovery · Sources fetched 2026-09-11 · Editorial standards
Nonacog Beta Pegol is a recovery research peptide. Nonacog Beta Pegol is a coagulation factor IX exogenous protein approved for the treatment of Hemophilia B.
Nonacog Beta Pegol is an exogenous protein that functions as a coagulation factor IX. It is approved by the FDA for the treatment of Hemophilia B, reaching Phase 4 clinical development for this indication. Research on Nonacog Beta Pegol includes reviews on its use in Haemophilia B, cost-consequence analyses based on real-world factor IX consumption and clinical outcomes, and evaluations of its long-term safety. Studies also cover assay experiences and results from international open-label phase 3 trials in children with hemophilia B.
1 Mechanism of action
Coagulation factor IX exogenous protein (exogenous protein)
2 Reported effects
Effects below are those reported in the published literature cited on this page. They are not claims of clinical benefit and not medical advice.
2.1 Indicated / studied for
- Hemophilia B
3 Chemical and physical properties
| Purity (typical) | Not independently verified |
|---|---|
| Storage | −20 °C, lyophilised powder, desiccated |
| Solubility | Sterile water / bacteriostatic water |
4 Research studies (8)
- Nonacog Beta Pegol: A Review in Haemophilia B
Drugs (2017) · Review - Treatment switch to nonacog beta pegol factor IX in hemophilia B: A Canadian cost-consequence analysis based on real-world factor IX consumption and clinical outcomes
Research and practice in thrombosis and haemostasis (2023) - FIXing postinfusion monitoring: Assay experiences with N9-GP (nonacog beta pegol; Refixia(®) ; Rebinyn(®) )
Haemophilia : the official journal of the World Federation of Hemophilia (2019) · Review - Evaluation of Nonacog Beta Pegol Long-term Safety in the Immune-deficient Rowett Nude Rat (Crl:NIH-Foxn1rnu)
Toxicologic pathology (2016) - Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial
Journal of thrombosis and haemostasis : JTH (2016) - Nonacog beta pegol prophylaxis in children with hemophilia B: safety, efficacy, and neurodevelopmental outcomes for up to 8 years
Research and practice in thrombosis and haemostasis (2024) - Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real-world, multicenter, retrospective study
Research and practice in thrombosis and haemostasis (2022) - Nonacog beta pegol (N9-GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients
Research and practice in thrombosis and haemostasis (2020)
5 Safety and risk profile
5.1 Regulatory status
Nonacog Beta Pegol is currently classified as FDA approved. Approval applies to specific clinical indications and dosing; research-grade material is not the approved product.
6 Frequently asked questions
- What is Nonacog Beta Pegol?
- Nonacog Beta Pegol is an exogenous protein that acts as a coagulation factor IX. It is used in medical treatments to help with blood clotting processes.
- What is Nonacog Beta Pegol used for?
- Nonacog Beta Pegol is used for the treatment of Hemophilia B. This condition is characterized by a deficiency in coagulation factor IX, which impairs blood clotting.
- How does Nonacog Beta Pegol work?
- Nonacog Beta Pegol works as a coagulation factor IX exogenous protein. It replaces or supplements the deficient factor IX in individuals with Hemophilia B, thereby aiding in the blood coagulation cascade.
- Is Nonacog Beta Pegol FDA approved?
- Yes, Nonacog Beta Pegol is FDA approved. It received its first approval in 2017 for its indicated use in treating Hemophilia B.
7 References
- Nonacog Beta Pegol — molecule record ChEMBL. View source
- Nonacog Beta Pegol — published literature (46 records) PubMed. View source
Related compounds
Entries that share a target, a mechanism, or a research area with Nonacog Beta Pegol.
Shares coagulation and factor pharmacology
Bradykinin is an endogenous human peptide involved in various physiological processes, including blood coagulation and inflammation.
Also recovery
A 28-amino acid thymic peptide that modulates T-cell function and cytokine balance. Studied clinically for chronic hepatitis B, sepsis, and vaccine response augmentation for over 30 years.
Also recovery
A single amino acid substitution turns GLP-2 from a 7-minute hormone into a drug that regrows intestinal villi. The only approved peptide that makes the gut physically bigger.
Also recovery
A synthetic ghrelin-mimetic hexapeptide that potently stimulates GH release through the ghrelin receptor. One of the first growth hormone secretagogues developed, with over 25 years of research history.
Also recovery
A 15-amino acid cytoprotective peptide derived from human gastric juice. Widely researched for wound healing, tendon repair, and GI protection across hundreds of animal studies.
Also recovery
The only human cathelicidin host-defense peptide. Kills bacteria, modulates inflammation, promotes wound healing, and is being studied for infections, sepsis, and tissue repair.